Ejection Fraction) trial is designed to determine the efficacy and safety of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan compared with valsartan in patients with chronic heart failure and preserved ejection fraction (HFpEF).
BACKGROUND HFpEF is highly prevalent, associated with substantial morbidity and mortality, and in need of effective therapies that improve outcomes. The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan, which has been shown to benefit patients with heart failure (HF) and reduced ejection fraction, demonstrated favorable physiologic effects in a phase II HFpEF trial.
METHODS
The PARAGON-HF trial is a randomized, double-blind, parallel group, active-controlled, event-driven trial comparing the long-term efficacy and safety of valsartan and sacubitril/valsartan in patients with chronic HFpEF (left ventricular ejection fraction $45%), New York Heart Association functional class II to IV symptoms, elevated natriuretic peptides, and evidence of structural heart disease. Before randomization, all patients entered sequential single-blind run-in periods to ensure tolerability of both drugs at half the target doses (i.e., valsartan titrated to 80 mg bid followed by sacubitril/valsartan 49/51 mg [100 mg] bid). The primary outcome is the composite of cardiovascular death and total (first and recurrent) HF hospitalizations.
CONCLUSIONS PARAGON-HF will determine whether sacubitril/valsartan is superior to angiotensin receptor abnormalities of ventricular-vascular coupling (7); increased cardiomyocyte stiffness; and comorbidityinduced systemic inflammation (8) . Four outcome trials using inhibitors of the renin-angiotensinaldosterone system (RAAS) did not meet their primary endpoints (9) (10) (11) (12) , and currently, no therapy has received regulatory approval to reduce morbidity and mortality (13, 14) . 
TRIAL DESIGN AND METHODS
PARAGON-HF is a randomized, double-blind, parallel group, active-controlled, 2-arm, event-driven trial comparing the long-term efficacy and safety of valsartan and sacubitril/valsartan in patients with chronic symptomatic HFpEF. The trial was designed by members of the steering committee in collaboration with the sponsor. The trial has been registered (NCT01920711).
PATIENTS. The final eligibility criteria are summarized in Table 1 . Briefly, patients were $50 years of age, had a left ventricular ejection fraction (LVEF) $45% by echocardiography within the 6 months before screening and symptoms of HF (NYHA functional class II to IV), required diuretic therapy for at least 30 days before screening, and had NT-proBNP >200 pg/ml if the patient had been hospitalized for HF within the past 9 months or >300 pg/ml without a recent HFH.
The NT-proBNP requirement was tripled if patients were in atrial fibrillation at screening. In addition, patients had to have evidence of structural heart disease, including either LVH (i.e., septal or posterior wall thickness $1.1 cm) or LA enlargement (i.e., width $3. Solomon et al. a) HF hospitalization (defined as HF listed as the major reason for hospitalization) within 9 months prior to screening visit and NT-proBNP >200 pg/ml for patients not in AF or >600 pg/ml for patients in AF on screening ECG, or b) NT-proBNP >300 pg/ml for patients not in AF or >900 pg/ml for patients in AF on the screening visit ECG Exclusion criteria 1. Any prior echocardiographic measurement of LVEF <40% 2. Acute coronary syndrome (including MI), cardiac surgery, other major cardiovascular surgery, or urgent PCI within the 3 months prior to visit 1 or an elective PCI within 30 days prior to visit 1 3. Any clinical event within the 6 months prior to visit 1 that could have reduced the LVEF (e.g., MI, CABG), unless an echocardiographic measurement was performed after the event confirming the LVEF to be $45% 4. Current acute decompensated HF requiring augmented therapy with diuretic agents, vasodilator agents, and/or inotropic drugs 5. Patients who require treatment with 2 or more of the following: an ACEI, an ARB, or a renin inhibitor 6. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes 7. Patients with a known history of angioedema 8. Probable alternative diagnoses that in the opinion of the investigator could account for the patient's HF symptoms (i.e., dyspnea, fatigue), such as significant pulmonary disease (including primary pulmonary hypertension), anemia, or obesity. Specifically, patients with the following are excluded: a) Severe pulmonary disease including COPD (i.e., requiring home oxygen, chronic nebulizer therapy, or chronic oral steroid therapy or hospitalized for pulmonary decompensation within 12 months) or b) Hemoglobin <10 g/dl, or c) Body mass index >40 kg/m Evidence of right-sided HF in the absence of left-sided structural heart disease 13. Known pericardial constriction, genetic hypertrophic cardiomyopathy, or infiltrative cardiomyopathy 14. Clinically significant congenital heart disease that could be the cause of the patient's symptoms and signs of HF 15. Presence of hemodynamically significant valvular heart disease in the opinion of the investigator 16. Stroke, transient ischemic attack, carotid surgery, or carotid angioplasty within the 3 months prior to visit 1 17. Coronary or carotid artery disease or valvular heart disease likely to require surgical or percutaneous intervention during the trial 18. Life-threatening or uncontrolled dysrhythmia, including symptomatic or sustained ventricular tachycardia and AF or atrial flutter with a resting ventricular rate >110 beats per minute 19. Patients with a cardiac resynchronization therapy device 20. Patients with prior major organ transplant or intent to transplant (i.e., on transplant list) 21. Any surgical or medical condition that in the opinion of the investigator may place the patient at higher risk from his/her participation in the study or is likely to prevent the patient from complying with the requirements of the study or completing the study 22. Any surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of study drugs, including but not limited to any of the following: any history of pancreatic injury, pancreatitis, or evidence of impaired pancreatic function/injury within the past 5 years For secondary endpoints, change from baseline in KCCQ clinical summary score at 8 months will be analyzed using a repeated-measures ANCOVA model, Reducing cardiovascular deaths and total worsening HF events. A subject will be defined as having a cardiovascular death or worsening HF event when the subject has: B Cardiovascular death, or B A hospitalization for HF, or B Received IV decongestive therapy (IV diuretic agents, IV nesiritide or other natriuretic peptide, IV inotropes, and IV nitroglycerin) that does not result in formal inpatient hospital admission, regardless of the setting (i.e., in an ED setting, in the physician's office, an outpatient treatment facility, and so on) Hospitalizations (all cause and cause specific) The number of days alive and out of hospital at 12 months Slowing the rate of decline in eGFR Delaying time to new-onset diabetes mellitus Reducing healthcare resource utilization (e.g., number of days/stays in intensive care unit, number of rehospitalizations, and number of ED visits for HF) 30-day HF hospital readmissions and readmission rate after a prior HF hospitalization Time between HF hospital readmissions The profile of pre-specified biomarkers (e.g., cardiac, vascular, renal, collagen, metabolism, inflammatory, and/or other relevant biomarkers) from baseline to pre-defined time points in a subset of patients The primary composite and secondary endpoints, and key exploratory endpoints in ACEI-intolerant patients Evaluating the changes in cognitive function (assessed by the MMSE) at 2 yrs To characterize sacubitril/valsartan and valsartan PK at steady state using population modeling and/or noncompartmental based methods in a subset of patients together with the mixed-effect logistic responder analyses for 5-point deterioration and 5-point improvement; change from baseline in NYHA functional class at 8 months will be analyzed using a repeated-measures proportional cumulative odds model; time to first renal impairment composite outcome and time to all-cause death will also be analyzed with Cox proportional hazard models. The multiplicity for the comparisons across the primary and secondary endpoints will be adjusted on the basis of a sequentially rejective multiple test procedure (25) . If the primary endpoint is statistically significant at the significance-level alpha (e.g., 1-sided level of 0.024 at the end), then the KCCQ and NYHA endpoints will be tested at level alpha/2. If one of them is statistically significant at this level, the other can be tested at level alpha. If both KCCQ and NYHA endpoints are statistically significant, the composite renal endpoint can be tested at level alpha. The all-cause mortality endpoint will be tested at level alpha, after the rejection of the primary hypothesis.
The endpoints for the exploratory objectives in Table 2 will also be analyzed using appropriate methods.
S t u d y d u r a t i o n , i n t e r i m a n a l y s e s , a n d e a r l y t e r m i n a t i o n . PARAGON-HF is an event-driven trial, and all randomized patients will be followed up until at least 1,847 total (first and recurrent) HFHs and cardiovascular deaths occur, with follow-up of $26 months after randomization for all noncensored patients to obtain the target power, unless the DMC recommends that the study be stopped earlier for efficacy or safety reasons. The minimum follow-up duration can be blindly re-estimated using the The inclusion criteria of PARAGON-HF were designed to mitigate issues that might have been problematic for prior HFpEF trials ( Table 3) . To ensure that patients enrolled had HF and that their signs and symptoms were not simply due to other disease states, all patients enrolled in PARAGON-HF after an early protocol amendment were required to have mild NP elevation, regardless of whether they were hospitalized for HF in the recent past. This criterion was designed to ensure that a patient would not be enrolled solely on the basis of an HFH, which might be difficult to verify. Additionally, all patients in PARAGON-HF were required to have structural heart disease, some degree of LVH or LA enlargement, both of which are known to be markers of risk in HFpEF (27, 28) . These criteria were not specifically required in all patients by prior HFpEF outcomes trials (Table 3) . KEY WORDS angiotensin receptor neprilysin inhibitor, heart failure with preserved ejection fraction, sacubitril, valsartan APPENDIX For a list of the PARAGON-HF study co-chairs and committee members as well as supplemental tables, please see the online version of this article.
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